Recently, using the interferon-gamma (IFN-g) ELISPOT we demonstrated that both hematopoetic and solid cancer patients host spontaneous T-cell responses against Mcl-1-derived peptides.
1,2 Thus, strong and frequent cytotoxic T lymphocytes (CTL) responses against Mcl-1 were detected in chronic lymphocytic leukemia (CLL) patients, melanoma patients, pancreatic cancer patients and breast cancer patients, whereas no responses could be detected in healthy individuals. We have identified several Mcl-1-derived peptide epitopes, for example, the HLA-A3-restricted peptide Mcl-1 95-103 (RLLFFAPTR). The IFN-g ELISPOT assay is one of the most useful techniques for immunological monitoring of CTL responses and has gained increased application as a measure of specific T-cell activation. However, it does not assess cell-mediated cytotoxicity directly as IFN-g secretion is not limited to cytolytic cells. Thus, although it has been shown that IFN-g ELISPOT reactivity in most cases correlates with the capacity to exhibit cytotoxic function, the formal proof for this notion can only be obtained directly. Letter to the Editor control. The Mcl-1-specific T-cell clone did not kill this cell line (Figure 1c) .
The lower rates of relapse in allogeneic transplantation compared with autologous bone marrow transplantation, the striking clinical benefit of donor-lymphocyte infusions as well as the finding that human T cells can destroy chemotherapyresistant cell lines from chronic myeloid leukemia and multiple myeloma, have prompted development of immunotherapeutic strategies against hematological cancers.
3 Among these approaches, active specific immunization or vaccination is emerging as a valuable tool to boost the adaptive immune system against malignant cells. In this regard, the identification of leukemia-associated antigens is crucial. However, very few antigens are characterized in a conceptual framework in which the biology, microenvironment, and conventional disease management have been taken into consideration. Myeloid cell factor-1 (Mcl-1) is a death-inhibiting member of the Bcl-2 family that is expressed in early monocyte differentiation. Elevated levels of Mcl-1 have been reported for a number of solid and hematopoitic cancers, for example, B-cell chronic lymphocytic leukemia (B-CLL) and in AML and ALL upon relapse. [4] [5] [6] In B-CLL patients, higher levels of Mcl-1 are strongly correlated with failure to achieve complete remission after single-agent therapy. In multiple myeloma, Mcl-1 plays an important role in the survival of malignant cells. 7 We have reported that spontanous Mcl-1-specific T-cell responses are frequent in cancer patients and that these T-cells are highly cytotoxic against cancer cells. Hence, Mcl-1 appears to be a very attactrive target for anticancer immunotherapy both in hematopoetic and solid cancers.
